Poly(ethyleneglycol) 500 Dimethylether as Novel Solvent for Injectable In Situ Forming Depots
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Poly(D,L-lactide-co-glycolide) (PLGA) solutions in poly(ethyleneglycol)600 (PEG600), N-methyl-2-pyrrolidone (NMP) and poly(ethyleneglycol)500dimethylether (PEG500DME) as a novel solvent, were investigated as suitable for use in injectable in situ forming depots (ISFD).
The hemolytic potential of the solvents was investigated. Viscosimetry was used to determine rheological properties of solvents and PLGA solutions. DSC was used to evaluate the stability of the PLGA solutions through investigation of the melting behavior of semicrystalline PEGs which depended on tempering and glass transition temperature of the PLGA. Phase separation was studied to determine ternary phase diagrams. In vitro release kinetics of the solvents and the surrogate methylene blue were investigated.
Significantly less hemolysis was observed for PEG500DME compared to PEG600 and NMP. Newtonian fluid properties were found for all polymer solutions. A melting point depression of the solvents was detected in presence of PLGA. The duration of tempering of the polymer solutions showed no impact on their melting behavior. The initial in vitro release of methylene blue was according to the solvent diffusion kinetics.
Low hemolytic potential, suitable viscosity for injection, stability of PLGA solutions in PEG500DME and the correlation between phase separation and in vitro release confirmed the potential of PEG500DME as a promising solvent for ISFD.
- Ravivarapu HB, Moyer KL, Dunn RL. Parameters affecting the efficacy of a sustained release polymeric implant of leuprolide. Int J Pharm. 2000;194:181–91. CrossRef
- International congress on harmonisation. Guideline: Impurities: Guideline for residual solvents Q3C(R3).
- Powell MF, Nguyen T, Baloian L. Compendium of excipients for parenteral formulations. PDA J Pharm Sci Technol. 1998;52:238–311.
- Kempe S, Metz H, Pereira PGC, Maeder K. Non-invasive in vivo evaluation of in situ forming PLGA implants by benchtop magnetic resonance imaging (BT-MRI) and EPR spectroscopy. Eur J Pharm Biopharm. 2009; doi:10.1016/j.ejpb.2009.06.008. accepted manuscript.
- Shively ML, Coonts BA, Renner WD, Southard JL, Bennett AT. Physico-chemical characterization of a polymeric injectable implant delivery system. J Control Release. 1995;33:237–243.
- Schoenhammer K, Petersen H, Guethlein F, Goepferich A. Injectable in-situ forming depot systems: PEG-DAE as a novel solvent for improved storage stability. Int J Pharm. 2008; doi:10.1016/j.ijpharm.2008.12.019. accepted manuscript.
- Ginés JM, Arias MJ, Rabasco AM, Novak C, Ruiz-Conde A, Sanchez-Soto PJ. Thermal characterization of polyethylene glycols applied in the pharmaceutical technology using differential scanning calorimetry and hot stage microscopy. J Therm Anal Calorim. 1996;46:291–304. CrossRef
- Kempe S, Metz H, Maeder K. Do in situ forming PLG/NMP implants behave similar in vitro and in vivo? A non-invasive and quantitative EPR investigation on the mechanisms of the implant formation process. J Control Release. 2008;130:220–5. CrossRef
- Astaneh R, Erfan M, Moghimi H, Mobedi H. Pharmaceutics, preformulation and drug delivery changes in morphology of in situ forming PLGA implant prepared by different polymer molecular weight and its effect on release behavior. J Pharm Sci. 2009;98:135–45. CrossRef
- Graham PD, Brodbeck KJ, McHugh AJ. Phase inversion dynamics of PLGA solutions related to drug delivery. J Control Release. 1999;58:233–45. CrossRef
- Wang L, Venkatraman S, Kleiner L. Drug release from injectable depots: two different in vitro mechanisms. J Control Release. 2004;99:207–16. CrossRef
- Astaneh R, Erfan M, Barzin J, Mobedi H, Moghimi H. Effects of ethyl benzoate on performance, morphology and erosion of PLGA implants formed in situ. Adv Polym Technol. 2008;27:17–26. CrossRef
- Brodbeck KJ, Pushpala S, McHugh AJ. Sustained release of human growth hormone from PLGA solution depots. Pharm Res. 1999;16:1825–9. CrossRef
- Drabkin D. The standardization of hemoglobin measurement. Am J Med Sci. 1949;217:710–1.
- Iwata M, Tanaka T, Nakamura Y, McGinity JW. Selection of the solvent system for the preparation of poly(D,L-lactic-co-glycolic acid) microspheres containing tumor necrosis factor-alpha (TNF-α). Int J Pharm. 1998;160:145–56.
- Kranz H, Brazeau GA, Napaporn J, Martin RL, Millard W, Bodmeier R. Myotoxicity studies of injectable biodegradable in-situ forming drug delivery systems. Int J Pharm. 2001;212:11–8.
- Rungseevijitprapa W, Bodmeier R. Injectability of biodegradable in situ forming microparticle systems (ISM). J Pharm Sci. 2009;36:524–31.
- Nema S, Washkuhn RJ, Brendel RJ. Excipients and their use in injectable products. PDA J Pharm Sci Technol. 1997;51:166–71.
- Nielsen SL. Adipose tissue blood flow determined by the washout of locally injected 133Xenon. Scand J Clin Lab Invest. 1972;29:31–6. CrossRef
- U.S.Food and Drug Administration. Inactive Ingredient Search for Approved Drug Products. (http://www.accessdata.fda.gov/scripts/cder/iig/index.cfm).
- Toraishi K, Yuizono Y, Nakamura N, Kato S, Aoki T, Ashida K, et al. Force requirements and insulin delivery profiles of four injection devices. Diabetes Technol Ther. 2005;7:629–36. CrossRef
- Brodbeck KJ, DesNoyer JR, McHugh AJ. Phase inversion dynamics of PLGA solutions related to drug delivery: Part II. The role of solution thermodynamics and bath-side mass transfer. J Control Release. 1999;62:333–44. CrossRef
- Poly(ethyleneglycol) 500 Dimethylether as Novel Solvent for Injectable In Situ Forming Depots
Volume 26, Issue 12 , pp 2568-2577
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- in situ forming depot
- Industry Sectors